XKRX
007570
Market cap98mUSD
Jul 10, Last price
8,570.00KRW
1D
-1.65%
1Q
-29.73%
Jan 2017
-80.02%
Name
Ilyang Pharmaceutical Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in South Korea, Ilyang Pharmaceutical Co.,Ltd operates as a significant enterprise within the pharmaceutical sector. The company offers an extensive array of medicinal products designed to address diverse health concerns, including treatments for cancer, circulatory ailments, endocrine and metabolic disorders, specific Cheonjiyang offerings, female hormone regulation, urinary tract issues, ophthalmological conditions, and liver diseases. Its portfolio further extends to digestive and respiratory system therapies, dermatological solutions, anti-inflammatory pain relievers, and neurological medications, alongside nutrient infusions, antibiotics, antifungal agents, insecticides, and vaccines. Beyond pharmaceuticals, Ilyang Pharmaceutical diversifies its product lines to include consumer health goods such as health drinks, daily food items, nutritional supplements, health foods, cosmetics, and various beverages. Moreover, it is a manufacturer of crucial pharmaceutical raw materials, producing a wide range of aluminum and magnesium compounds like aluminum hydroxide gel, magnesium hydroxide, hydrotalcite, magaldrate, and others. Established in 1946 and headquartered in Yongin, South Korea, the company, initially known as Il-Yang Pharm. Ind. Co. before its name change in May 1991, also exports its products to approximately 14 countries globally.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||